

| Name of the Issuer: | | Concord Biotech Limited | | Last updated on: February 15, 2026 | |
|--|---|---|--|--|---|
| 1 | Type of Issue (IPO / FPO) Source: Prospectus dated August 9, 2023 | IPO | | | |
| 2 | Issue Size (Rs. Million)* - Fresh Issue Size (Rs. Millions) - Offer for Sale Component (Rs. Millions) *Source: Prospectus dated August 9, 2023 | 15,505.21 NA 15,505.21 | | | |
| 3 | Grade of issue along with name of the rating agency Name Grade Source: Prospectus dated August 9, 2023 | Not Applicable Not Applicable | | | |
| 4 | Subscription Level (Number of times) *Source: Basis of Allotment Advertisement dated August 17, 2023 *The above figure is after technical rejections | 17.73* | | | |
| 5 | QIB Holding (as a % of outstanding capital) as disclosed to stock exchanges | | | | |
| Particulars | | | | % | |
| (i) allotment in the issue ⁽¹⁾ | | | | 10.00% | |
| (ii) at the end of 1st Quarter immediately after the listing (September 30, 2023) | | | | 15.48% | |
| (iii) at the end of 1st FY (March 31, 2024) | | | | 14.94% | |
| (iv) at the end of 2nd FY (March 31, 2025)* | | | | 18.51 | |
| (v) at the end of 3rd FY (March 31, 2026)* | | | | Not Available | |
| *QIB Holding not disclosed as reporting for the relevant period / fiscal year has not been completed. | | | | | |
| (1) Source: Reporting with the NSE. Represents holding of Institutions category | | | | | |
| 6 | Financials of the issuer (In Rs. Millions) | | | | |
| Parameters | | 1st FY (March 31, 2024) | 2nd FY (March 31, 2025) | 3rd FY (March 31, 2026)* | |
| Income from Operations | | 10,169.39 | 12,000.87 | Not Available | |
| Net Profit for the period | | 3,081.03 | 3,716.23 | Not Available | |
| Paid-up equity share capital | | 104.62 | 104.62 | Not Available | |
| Reserves excluding revaluation reserves | | 15,161.84 | 18,022.56 | Not Available | |
| *Financials not disclosed as reporting for the relevant fiscal year has not been completed. | | | | | |
| 7 | Trading Status in the scrip of the issuer Company's Equity Shares are listed on both BSE Limited and National Stock Exchange of India Limited The Shares have not been suspended or delisted. | | | | |
| Particulars | | | | Status | |
| (i) at the end of 1st FY (March 31, 2024) | | | | Frequently traded | |
| (ii) at the end of 2nd FY (March 31, 2025)* | | | | Frequently traded | |
| (iii) at the end of 3rd FY (March 31, 2026)* | | | | Not Available | |
| *Trading status not disclosed as the relevant fiscal year has not been completed. | | | | | |
| 8 | Change in Directors of issuer from the disclosures in the offer document | | | | |
| Particulars | | Name of the Director | | Appointed / Resigned | |
| (i) at the end of 1st FY (March 31, 2024) | | Amit Varma | | Resigned | |
| | | Anil Katyal | | Resigned | |
| | | Utpal Hemendra Sheth | | Resigned | |
| (ii) at the end of 2nd FY (March 31, 2025)* | | Nil | | Nil | |
| (iii) at the end of 3rd FY (March 31, 2026)* | | Not Available | | Not Available | |
| Source: Stock Exchange Filings | | | | | |
| * Changes in Directors not disclosed as the relevant fiscal year has not been completed. | | | | | |
| 9 | Status of implementation of project/ commencement of commercial production | | | | |
| (i) as disclosed in the offer document | | | | | Not Applicable* |
| (ii) Actual implementation | | | | | Not Applicable* |
| (iii) Reasons for delay in implementation, if any *The issue was a complete Offer for Sale | | | | | Not Applicable* |
| 10 | Status of utilization of issue proceeds | | | | |
| (i) as disclosed in the offer document | | | | | Not applicable* |
| (ii) Actual implementation | | | | | Not applicable* |
| (iii) Reasons for delay in implementation, if any *The issue was a complete Offer for Sale | | | | | Not applicable* |
| 11 | Comments of monitoring agency | | | | |
| (a) Comments on use of funds | | | | | Not Applicable* |
| (b) Comments on deviation, if any, in the use of proceeds of the issue from the objects stated in the offer document | | | | | |
| (c) Any other reservations expressed by the monitoring agency about the end use of funds | | | | | |
| *As the issue was a complete OFS there was no requirement of appointing a monitoring agency | | | | | |
| 12 | Pricing Data | | | | |
| Issue Price (Rs.): | | 741 | | | |
| Designated Stock Exchange: | | NSE | | | |
| Listing Date: | | 18-Aug-22 | | | |
| Price parameters | At close of listing day (August 18, 2023) | At close of 30th calendar day from listing day (September 16, 2023) ⁽¹⁾ | At close of 90th calendar day from listing day (November 15, 2023) ⁽²⁾ | As at the end of 1st FY after the listing of the issue (March 31, 2024) ⁽³⁾ | |
| | | | | Closing price | High (during the FY) |
| | | | | Low (during the FY) | |
| Market Price on Designated Stock Exchange ⁽⁶⁾ | 942.80 | 1,013.85 | 1,362.80 | 1,488.15 | 1,565.00 |
| NIFTY 50 ⁽⁶⁾ | 19,310.15 | 20,192.35 | 19,675.45 | 22,326.90 | 22,516.00 |
| Sectoral Index ⁽⁶⁾ | Not Applicable | | | Not Applicable | |
| Price parameters | As at the end of 2nd FY after the listing of the issue (March 31, 2025) ⁽³⁾⁽⁴⁾ | | | As at the end of 3rd FY after the listing of the issue (March 31, 2026) ⁽³⁾⁽⁴⁾ | |
| | Closing price | High (during the FY) | Low (during the FY) | Closing price | High (during the FY) |
| | | | | Low (during the FY) | |
| Market Price on Designated Stock Exchange ⁽⁶⁾ | 1,676.35 | 2,596.70 | 1,391.80 | Not Available | Not Available |
| NIFTY 50 ⁽⁶⁾ | 23,519.35 | 26,216.05 | 21,884.50 | Not Available | Not Available |
| Sectoral Index ⁽⁶⁾ | Not Applicable | | | Not Applicable | |
| Source: NSE website | | | | | |
| Note: | | | | | |
| (1) 30th calendar day shall be taken as listing date plus 29 calendar days. | | | | | |
| (2) 90th calendar day shall be taken as listing date plus 89 calendar days. | | | | | |
| (3) High and Low based on intra day prices | | | | | |
| (4) Pricing data not disclosed as the relevant period/ fiscal year has not completed | | | | | |
| (5) In case of any reporting day falling on a holiday, previous trading day prices/values have been disclosed. | | | | | |
| (6) Comparable Sectoral Index is not available | | | | | |
| 13 | Basis for Issue Price | | | | |
| Accounting ratio | As disclosed in the offer document ⁽¹⁾ | | At the end of 1st FY (March 31, 2024) | At the end of 2nd FY (March 31, 2025) ⁽²⁾ | At the end of 3rd FY (March 31, 2026) ⁽²⁾ |
| EPS | Issuer: | | | | |
| | Consolidated (Basic) | 22.95 | 29.45 | 35.52 | Not Available |
| | Consolidated (Diluted) | 22.95 | 29.45 | 35.52 | Not Available |
| | Peer Group: (Consolidated) | | | | |
| | Divi's Laboratories Limited | 68.69 | 60.27 | 82.53 | Not Available |

| | | | | | |
|-----------------------------------|-----------------------------------|---------------|---------------|---------------|---------------|
| | Suven Pharmaceuticals Limited | 16.16 | 11.80 | 10.52 | Not Available |
| | Laurus Labs Limited | 14.64 | 2.98 | 6.65 | |
| | Shilpa Medicare Limited | -3.74 | 3.67 | 8.04 | Not Available |
| | Industry Avg: | 23.94 | 19.68 | 26.94 | N.A. |
| Price to Earnings Ratio (P/E) | Issuer: | | | | |
| | Consolidated (Basic / Diluted) | 32.29 | 50.53 | 47.19 | Not Available |
| | Peer Group: (Consolidated) | | | | |
| | Divi's Laboratories Limited | 54.15 | 57.16 | 69.95 | Not Available |
| | Suven Pharmaceuticals Limited | 30.08 | 57.38 | 110.25 | Not Available |
| | Laurus Labs Limited | 23.7 | 131.66 | 92.30 | Not Available |
| | Shilpa Medicare Limited | NA | 125.49 | 82.46 | Not Available |
| | Industry Avg: | 35.98 | 92.92 | 88.74 | N.A. |
| | Issuer: | | | | |
| | Consolidated | 20.06% | 20.2% | 20.50% | Not Available |
| Peer Group: (Consolidated) | | | | | |
| Divi's Laboratories Limited | 14.28% | 11.6% | 14.64% | Not Available | |
| Suven Pharmaceuticals Limited | 23.70% | 14.6% | 15.61% | Not Available | |
| Laurus Labs Limited | 19.68% | 4.1% | 8.01% | Not Available | |
| Shilpa Medicare Limited | NA | 1.8% | 3.30% | Not Available | |
| Industry Avg: | 19.22% | 8.0% | 10.39% | N.A. | |
| NAV per Equity Share | Issuer: | | | | |
| | Consolidated | 123.31 | 145.93 | 173.27 | Not Available |
| | Peer Group: (Consolidated) | | | | |
| | Divi's Laboratories Limited | 480.93 | 517.99 | 564.87 | Not Available |
| | Suven Pharmaceuticals Limited | 68.16 | 80.56 | 72.30 | Not Available |
| | Laurus Labs Limited | 75.16 | 76.27 | 85.35 | Not Available |
| | Shilpa Medicare Limited | 204.41 | 208.37 | 241.71 | Not Available |
| | Industry Avg: | 207.17 | 220.80 | 241.06 | N.A. |

Notes:

(1) Sourced from Prospectus dated August 9, 2023

(2) Information not provided as the relevant fiscal year has not completed

Key ratios for the Company for the three fiscal years stated above shall be calculated as follows:

(i) Basic Earnings per Share (Rs.) = net profit after tax and adjustments, attributable to equity shareholders / Weighted average no. of equity shares outstanding during the fiscal year.

Earnings per share calculations are in accordance with the notified Ind AS 33 'Earnings per share' notified accounting standard by the Companies (Indian Accounting Standards) Rules of 2015 (as amended).

(ii) Diluted Earnings per Share (Rs.) = net profit after tax and adjustments, attributable to equity shareholders (after adjusting profit impact of dilutive potential equity shares, if any) / the aggregate of weighted average number of Equity shares outstanding during the year and the weighted average number of Equity shares that would be issued on conversion of all the dilutive potential Equity shares into Equity shares.

(iii) Total Income = Revenue from Operations and Other Income

(iv) P/E (Basic/Diluted) - Closing Market Price at the end of relevant fiscal year end on NSE/ Basic/Diluted EPS

(v) Return on Net Worth (%) = Net profit after tax, available for equity shareholders / Net worth at the end of the fiscal year.

(vi) Net Asset Value per Equity Share = Net worth at the end of the fiscal year / Number of equity shares outstanding as at the end of fiscal year

14 Any other material information

| Date of disclosure | Announcement |
|-----------------------------|--|
| 18-Aug-23 | Listing of equity shares of Concord Biotech Limited |
| 19-Aug-23 | Company has informed the Stock Exchanges that Mr. Amit Varma, Non-Executive Non-Independent Director of the Company, has resigned pursuant to sale of shares held by Helix |
| 22-Aug-23 | Company has informed the Stock Exchanges that the United States Food And Drug Administration (USFDA) had conducted an inspection at Company's Manufacturing Unit III, Plot No. 84 |
| 25-Aug-23 | Company has informed the Stock Exchanges that Mr. Anil Kalyal, Independent Director of the company has tendered his resignation as the Independent Director of the company, with effect |
| 6-Sep-23 | Company has informed the Stock Exchanges that the Board of Directors of the Company, at its meeting held on Wednesday, September 06, 2023, has inter-alia, approved Unaudited |
| 30-Sep-23 | Company has informed the Stock Exchanges that Mr. Utpal Hemendra Sheh, Independent Director of the company has tendered his resignation with effect from 30th September, 2023 citing |
| 8-Nov-23 | Company has informed the Stock Exchanges that the Board of Directors of the company at its meeting held on Wednesday, 08th November, 2023 has inter-alia approved unaudited |
| 22-Feb-24 | Intimation about closure of Inspection of Ministry of Health Pharmacy and Poisons Board, Republic of Kenya at Valthera (Unit II) of the Company |
| 23-May-24 | Company has informed that Board has approved appointment of BSR & Co. LLP as Statutory Auditors of the Company for a First term of Consecutive 5 years in place of Existing Statutory |
| 29-May-24 | The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for 1575773 Ontario INC |
| 24-Dec-24 | Closure of Trading Window |
| 16-Jan-25 | M/s Concord Biotech Limited (Company) has today, entered into a Share Purchase Agreement (SPA) with M/s Clean Max Everglades Limited (Clean Max) and M/s Clean Max Enviro Energy Solutions Private Limited (CMEESPL), whereby the Company will acquire 26% equity shares of Clean Max from CMEESPL |
| 20-Feb-25 | Enclosed herewith Intimation regarding successful completion of Inspection by Ministry of Food and Drug Safety (MFDS) at Manufacturing Unit-1 situated at Dholka. |
| 22-Mar-25 | Closure of Trading Window |
| 25-Mar-25 | Enclosed herewith announcement about successfully commissioned and commenced production of Injectable at our Manufacturing facility situated at Valthera. |
| 8-Apr-25 | Disclosure Under Of SEBI (LODR) Regulations, 2015 'Concord Biotech Secures Abbreviated New Drug Application (ANDA) Approval To Market Terifunomide Tablets, 7 Mg And 14 Mg, In The US |
| 13-May-25 | Pursuant to Reg 30 of the SEBI(LODR) 2015, this is to inform that CS Prakash Sajani, vide letter dated 13/05/2025, has tendered his resignation from the post of Company Secretary and compliance officer with effect from 29/05/2025 after closure of working hours |
| 29-May-25 | On recommendation of NRC, the board of directors of the company, appointed Ms. Hina Patel(M.No-A56541), who is already in employment of the company. She is appointed as a company secretary and compliance officer of the company, as Key managerial personnel of the company with effect from 30th May, 2025 |
| 24-Jun-25 | Company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection carried out by them at our API facility at Dholka from 28th April 2025 till 2nd May 2025. |
| 2-Jul-25 | M/s. Concord Biotech Limited has made an equity investment of USD 1,500 in Stellon Biotech Inc. |
| 18-Jul-25 | Completion of the European Union Good Manufacturing Practice (EU GMP) inspection at our Active Pharmaceutical Ingredient (API) manufacturing facility located in Dholka, Gujarat. |
| 22-Jul-25 | Incorporation of Concord's Wholly Owned Subsidiary Company, namely, "Concord Lifegen Limited" with objective to carry out marketing, sales, and distribution of pharmaceutical products |
| 26-Jul-25 | Intimation of successful completion of Russian GMP inspection at our API Facility in Dholka |
| 8-Aug-25 | Record date for final dividend |
| 8-Oct-25 | Intimation of Successful Completion of NAFDAC Inspection at our Oral Solid Dosage Unit-2, facility located at Valthera |
| 13-Nov-25 | Board approved to Invest by way of acquiring 100 % equity share capital of M/s Cellimune Biotech Private Limited. Upon recommendation of Audit committee, board approved invest upto Rs. 10 Crores in Captive Hybrid Solar Power Project for Limbasi Plant by entering into an agreement with relevant party |
| 8-Dec-25 | Announcement under Regulation 30 (LODR)-Change in Management, Early retirement of Chief Financial Officer |
| 18-Dec-25 | Board Meeting Outcome for Appointment Of CFO And KMP, appointment of Mr. Raviraj Karia as Chief Financial Officer and KMP |
| 24-Dec-25 | Ms. Hina Patel, has tendered her resignation from the post of Company Secretary and Compliance Officer |
| 9-Feb-26 | Clarification regarding increase in volume. |
| 11-Feb-26 | Board of Directors of the Company, appointed Mr. Paritosh Trivedi (A63623) as Company Secretary, Compliance Officer and Nodal Officer of the Company with effect from February 11, 2026 |
| Source: NSE and BSE website | |

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, as applicable.

For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com.